Oppenheimer Maintains Outperform on TransMedics Group, Raises Price Target to $175
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Suraj Kalia maintains TransMedics Group (NASDAQ:TMDX) with a Outperform and raises the price target from $150 to $175.
Oppenheimer analyst Suraj Kalia maintains TransMedics Group (NASDAQ:TMDX) with a Outperform and raises the price target from $150 to $175.